1
REGN
REGENERON PHARMACEUTICALS · Health Care
Consensus score 1/100 · #210 this quarter · tier-weighted across tracked managers
↓DivergingPrice action since filingas of 2026-06-05
vs 50-day avg
-10.1%
21-day momentum
-11.9%
recent volume
1.57×
13F filings lag ~45 days; this is current price/volume action on top — a technical read, not a prediction.
S4· DecliningStage Analysis · Weinstein
vs 30-wk avg
-13.5%
30-wk MA slope
+1.3%
rel. strength
-15.4
52-wk range
46%
Declining — below a falling 30-week trend, lagging the market. Weinstein says avoid. Based on the 30-week (150-day) moving average + slope, Mansfield relative strength vs SPY, and volume. Technical read, not advice.
Holders
2
tracked managers
New this Q
0
opened a position
Avg weight
2.5%
of their portfolios
Combined value
$101M
held, at quarter-end
Who’s holding it Q1 2026, by position size
| Manager | Position size | Value | Change |
|---|---|---|---|
| Southeastern / Longleaf Deep value | 5.0% | $101M | TRIM |
| Horizon Kinetics Franchise/inflation | 0.0% | $522K | TRIM |
Position size = share of that manager’s reported long US-equity portfolio. The consensus score weights each holder by quality tier, position size, and whether they were buying or trimming — then discounts very crowded names. It measures agreement among these managers, not expected return.